Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
5 studies found for:    PFEIFFER SYNDROME
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Terminated Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
Condition: Medical Oncology
Intervention: Drug: BAY1187982
2 Recruiting A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Condition: Advanced Cholangiocarcinoma
Intervention: Drug: BGJ398
3 Active, not recruiting Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Condition: Solid Tumor
Intervention: Drug: ARQ 087
4 Recruiting Dovitinib for Gastric Cancer With FGFR2 Amplification
Condition: Gastric Cancer
Intervention: Drug: Dovitinib
5 Not yet recruiting Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer
Conditions: FGFR Gene Amplification;   FGFR1 Gene Amplification;   FGFR2 Gene Amplification;   FGFR2 Gene Mutation;   FGFR3 Gene Mutation;   Head and Neck Squamous Cell Carcinoma;   Human Papillomavirus Infection;   Recurrent Head and Neck Carcinoma;   Recurrent Nasopharynx Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: pan FGFR Kinase Inhibitor BGJ398

Study has passed its completion date and status has not been verified in more than two years.